Farmas USA

CITI downgrade ARIA to SELL.

edito: http://www.streetinsider.com/Analyst+Comments/Citi+Downgrades+ARIAD+Pharmaceuticals+%28ARIA%29+to+Sell%3B+Potential+Negatives+Outweigh+Positives/9025446.html?si_client=st

http://www.4-traders.com/PEREGRINE-PHARMACEUTICALS-11063/news/Peregrine-Pharmaceuticals-Receives-FDA-Fast-Track-Designation-for-Its-Immunotherapy-Bavituximab-as-a-17753601/

PPHM +30% en pre

Hoy de certeza se sube..y pronto tapara el hueco de la dilucion ..
Mast Therapeutics Announces Positive Data In Model Of Heart Failure
http://www.masttherapeutics.com/investors/news/

0.500 0.000 (0.00%)
Pre-market: 0.570 +0.070 (14.05%)

Patente para BAXS
http://www.4-traders.com/BAXANO-SURGICAL-INC-13362453/news/Baxano-Surgical-Inc--Baxano-Surgical-Assigned-Patent-17752786/

MSTX

Ya sabemos el por que del movimiento de los insiders del viernes :-)

Otra vez pegándole el plazo a ONVO....vaya comienzo de año q lleva!!!

DNDN.
Many investors appear to be quite bearish Dendreon Corporation (DNDN) especially if you look at the percentage of the float that is sold short for this stock. Currently, 35.6% of the float is sold short, suggesting an extreme level of bearishness for DNDN.

However, it is worth noting that earnings estimates have actually been moving higher for the company, despite the pessimism. Thanks to these rising estimates, we actually have a Zacks Rank #2 (Buy) on DNDN, so we clearly don’t believe in the negativity surrounding this firm, and are instead looking for shares of DNDN to move higher in the weeks ahead.
http://www.zacks.com/stock/news/118691/is-a-short-squeeze-ahead-for-dendreon-corporation-dndn
**
Nota: Hace semanas que os vengo avisando, apoyandome en grafico pienso lo mismo que este comentario.

BAXS se va por lo de la patente +10%